Prevalence and impact of hepatitis B and C virus co‐infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana
Identifieur interne : 000763 ( Main/Exploration ); précédent : 000762; suivant : 000764Prevalence and impact of hepatitis B and C virus co‐infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana
Auteurs : Kwamena William Coleman Sagoe [Ghana] ; Afrakoma Adjoa Agyei [Ghana] ; Francesca Ziga [Ghana] ; Margaret Lartey [Ghana] ; Theophilus K. Adiku [Ghana] ; Makafui Seshi [Ghana] ; Max Q. Arens [États-Unis] ; Julius Abraham Addo Mingle [Ghana]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 2012-01.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (administration et posologie), Anticorps de l'hépatite C (sang), Antigènes de surface du virus de l'hépatite B (sang), Charge virale, Co-infection (épidémiologie), Comorbidité, Femelle, Ghana, Humains, Hépatite B (), Hépatite B (épidémiologie), Hépatite C (), Hépatite C (épidémiologie), Immunoglobuline M (sang), Infections à VIH (), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification).
- MESH :
- administration et posologie : Agents antiVIH.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- sang : Anticorps de l'hépatite C, Antigènes de surface du virus de l'hépatite B, Immunoglobuline M.
- traitement médicamenteux : Infections à VIH.
- virologie : Infections à VIH.
- épidémiologie : Co-infection, Hépatite B, Hépatite C.
- Wicri :
English descriptors
- KwdEn :
- Active antiretroviral therapy, Adewole, Adult, Anti-HIV Agents (administration & dosage), Antiretroviral, Antiretroviral Therapy, Highly Active (methods), Antiretroviral therapy, Baseline parameters, CD4 Lymphocyte Count, Chronic hepatitis, Clinical disease, Cobas amplicor, Cohort, Coinfection (epidemiology), Comorbidity, Female, General biologicals corp, Ghana, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (virology), HIV-1 (isolation & purification), Haart, Harania, Hbeag, Hbsag, Hepatitis, Hepatitis B (complications), Hepatitis B (epidemiology), Hepatitis B Surface Antigens (blood), Hepatitis C (complications), Hepatitis C (epidemiology), Hepatitis C Antibodies (blood), Hepatitis virus, Hepatitis viruses, High prevalence, Humans, Idoko, Immunoglobulin M (blood), Infection, Male, Median, Middle Aged, Natural history, Nigerian cohort, Nigerian patients, Occult hepatitis, Opportunistic infections, Otegbayo, Plasma samples, Similar results, Teaching hospital, Viral, Viral Load, Viral load, Virol, Virus infection, West africa, Wiley periodicals.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents.
- chemical , blood : Hepatitis B Surface Antigens, Hepatitis C Antibodies, Immunoglobulin M.
- geographic : Ghana.
- complications : HIV Infections, Hepatitis B, Hepatitis C.
- drug therapy : HIV Infections.
- epidemiology : Coinfection, Hepatitis B, Hepatitis C.
- isolation & purification : HIV-1.
- methods : Antiretroviral Therapy, Highly Active.
- virology : HIV Infections.
- Teeft :
- Active antiretroviral therapy, Adewole, Adult, Antiretroviral, Antiretroviral therapy, Baseline parameters, CD4 Lymphocyte Count, Chronic hepatitis, Clinical disease, Cobas amplicor, Cohort, Comorbidity, Female, General biologicals corp, Ghana, Haart, Harania, Hbeag, Hbsag, Hepatitis, Hepatitis virus, Hepatitis viruses, High prevalence, Humans, Idoko, Infection, Male, Median, Middle Aged, Natural history, Nigerian cohort, Nigerian patients, Occult hepatitis, Opportunistic infections, Otegbayo, Plasma samples, Similar results, Teaching hospital, Viral, Viral Load, Viral load, Virol, Virus infection, West africa, Wiley periodicals.
Abstract
Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co‐infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti‐HBe, and anti‐HBc IgM. The viral load of HIV‐1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti‐HCV, respectively. None of the patients had anti‐HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti‐HBe, respectively. In patients with measurement of CD4+ undertaken within 1 month (n = 83), CD4+ count was significantly lower in patients with HBeAg (median [IQR], 81 [22–144]) as compared to those with anti‐HBe (median [IQR], 210 [197–222]) (P = 0.002, CI: −96.46 to 51.21). However, those with HIV mono‐infection had similar CD4+ counts (median [IQR], 57 [14–159]) compared to those with HBeAg (P = 1.0, CI: −71.75 to 73.66). Similar results were obtained if CD4+ count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti‐HCV did not affect CD4+ and viral loads of HIV‐1 in plasma but patients with HIV and HBV co‐infection who had HBeAg had more severe immune suppression as compared to those with anti‐HBe. This may have implication for initiating HAART in HBV endemic areas. J. Med. Virol. 84:6–10, 2011. © 2011 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/jmv.22262
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000068
- to stream Istex, to step Curation: 000068
- to stream Istex, to step Checkpoint: 000052
- to stream PubMed, to step Corpus: 000121
- to stream PubMed, to step Curation: 000121
- to stream PubMed, to step Checkpoint: 000121
- to stream Ncbi, to step Merge: 000464
- to stream Ncbi, to step Curation: 000464
- to stream Ncbi, to step Checkpoint: 000464
- to stream Main, to step Merge: 000764
- to stream Main, to step Curation: 000763
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence and impact of hepatitis B and C virus co‐infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><country>Ghana</country><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university" n="3">Université du Ghana</orgName></affiliation></author><author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name></author><author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name></author><author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q." last="Arens">Max Q. Arens</name></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8F60EE30E7B640FE6D29FA7E99D47FBB6B67536</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/jmv.22262</idno><idno type="url">https://api.istex.fr/document/D8F60EE30E7B640FE6D29FA7E99D47FBB6B67536/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000068</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000068</idno><idno type="wicri:Area/Istex/Curation">000068</idno><idno type="wicri:Area/Istex/Checkpoint">000052</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000052</idno><idno type="wicri:doubleKey">0146-6615:2012:Sagoe K:prevalence:and:impact</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22095533</idno><idno type="wicri:Area/PubMed/Corpus">000121</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000121</idno><idno type="wicri:Area/PubMed/Curation">000121</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000121</idno><idno type="wicri:Area/PubMed/Checkpoint">000121</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000121</idno><idno type="wicri:Area/Ncbi/Merge">000464</idno><idno type="wicri:Area/Ncbi/Curation">000464</idno><idno type="wicri:Area/Ncbi/Checkpoint">000464</idno><idno type="wicri:Area/Main/Merge">000764</idno><idno type="wicri:Area/Main/Curation">000763</idno><idno type="wicri:Area/Main/Exploration">000763</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prevalence and impact of hepatitis B and C virus co‐infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">Ghana</country><wicri:regionArea>P.O. Box 4236, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Pharmacy Department, Korle‐Bu Teaching Hospital, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university" n="3">Université du Ghana</orgName></affiliation></author><author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q." last="Arens">Max Q. Arens</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School, St. Louis</wicri:cityArea></affiliation></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">84</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="6">6</biblScope><biblScope unit="page" to="10">10</biblScope><biblScope unit="page-count">5</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-01">2012-01</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Active antiretroviral therapy</term><term>Adewole</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Antiretroviral</term><term>Antiretroviral Therapy, Highly Active (methods)</term><term>Antiretroviral therapy</term><term>Baseline parameters</term><term>CD4 Lymphocyte Count</term><term>Chronic hepatitis</term><term>Clinical disease</term><term>Cobas amplicor</term><term>Cohort</term><term>Coinfection (epidemiology)</term><term>Comorbidity</term><term>Female</term><term>General biologicals corp</term><term>Ghana</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>HIV-1 (isolation & purification)</term><term>Haart</term><term>Harania</term><term>Hbeag</term><term>Hbsag</term><term>Hepatitis</term><term>Hepatitis B (complications)</term><term>Hepatitis B (epidemiology)</term><term>Hepatitis B Surface Antigens (blood)</term><term>Hepatitis C (complications)</term><term>Hepatitis C (epidemiology)</term><term>Hepatitis C Antibodies (blood)</term><term>Hepatitis virus</term><term>Hepatitis viruses</term><term>High prevalence</term><term>Humans</term><term>Idoko</term><term>Immunoglobulin M (blood)</term><term>Infection</term><term>Male</term><term>Median</term><term>Middle Aged</term><term>Natural history</term><term>Nigerian cohort</term><term>Nigerian patients</term><term>Occult hepatitis</term><term>Opportunistic infections</term><term>Otegbayo</term><term>Plasma samples</term><term>Similar results</term><term>Teaching hospital</term><term>Viral</term><term>Viral Load</term><term>Viral load</term><term>Virol</term><term>Virus infection</term><term>West africa</term><term>Wiley periodicals</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (administration et posologie)</term><term>Anticorps de l'hépatite C (sang)</term><term>Antigènes de surface du virus de l'hépatite B (sang)</term><term>Charge virale</term><term>Co-infection (épidémiologie)</term><term>Comorbidité</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B ()</term><term>Hépatite B (épidémiologie)</term><term>Hépatite C ()</term><term>Hépatite C (épidémiologie)</term><term>Immunoglobuline M (sang)</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Thérapie antirétrovirale hautement active ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Hepatitis B Surface Antigens</term><term>Hepatitis C Antibodies</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coinfection</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps de l'hépatite C</term><term>Antigènes de surface du virus de l'hépatite B</term><term>Immunoglobuline M</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Co-infection</term><term>Hépatite B</term><term>Hépatite C</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Active antiretroviral therapy</term><term>Adewole</term><term>Adult</term><term>Antiretroviral</term><term>Antiretroviral therapy</term><term>Baseline parameters</term><term>CD4 Lymphocyte Count</term><term>Chronic hepatitis</term><term>Clinical disease</term><term>Cobas amplicor</term><term>Cohort</term><term>Comorbidity</term><term>Female</term><term>General biologicals corp</term><term>Ghana</term><term>Haart</term><term>Harania</term><term>Hbeag</term><term>Hbsag</term><term>Hepatitis</term><term>Hepatitis virus</term><term>Hepatitis viruses</term><term>High prevalence</term><term>Humans</term><term>Idoko</term><term>Infection</term><term>Male</term><term>Median</term><term>Middle Aged</term><term>Natural history</term><term>Nigerian cohort</term><term>Nigerian patients</term><term>Occult hepatitis</term><term>Opportunistic infections</term><term>Otegbayo</term><term>Plasma samples</term><term>Similar results</term><term>Teaching hospital</term><term>Viral</term><term>Viral Load</term><term>Viral load</term><term>Virol</term><term>Virus infection</term><term>West africa</term><term>Wiley periodicals</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Comorbidité</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Hépatite B</term><term>Hépatite C</term><term>Infections à VIH</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Thérapie antirétrovirale hautement active</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co‐infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti‐HBe, and anti‐HBc IgM. The viral load of HIV‐1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti‐HCV, respectively. None of the patients had anti‐HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti‐HBe, respectively. In patients with measurement of CD4+ undertaken within 1 month (n = 83), CD4+ count was significantly lower in patients with HBeAg (median [IQR], 81 [22–144]) as compared to those with anti‐HBe (median [IQR], 210 [197–222]) (P = 0.002, CI: −96.46 to 51.21). However, those with HIV mono‐infection had similar CD4+ counts (median [IQR], 57 [14–159]) compared to those with HBeAg (P = 1.0, CI: −71.75 to 73.66). Similar results were obtained if CD4+ count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti‐HCV did not affect CD4+ and viral loads of HIV‐1 in plasma but patients with HIV and HBV co‐infection who had HBeAg had more severe immune suppression as compared to those with anti‐HBe. This may have implication for initiating HAART in HBV endemic areas. J. Med. Virol. 84:6–10, 2011. © 2011 Wiley Periodicals, Inc.</div></front></TEI><affiliations><list><country><li>Ghana</li><li>États-Unis</li></country><region><li>Missouri (État)</li><li>Région du Grand Accra</li></region><settlement><li>Accra</li><li>Legon (Ghana)</li></settlement><orgName><li>Université du Ghana</li></orgName></list><tree><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name></region><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K." last="Adiku">Theophilus K. Adiku</name><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name></country><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q." last="Arens">Max Q. Arens</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000763 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000763 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D8F60EE30E7B640FE6D29FA7E99D47FBB6B67536
|texte= Prevalence and impact of hepatitis B and C virus co‐infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana
}}
| This area was generated with Dilib version V0.6.31. |  |